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Abstract
Background:  Previous studies have shown that there is a time-dependent upregulation of
contractile endothelin B (ETB) receptors in middle cerebral arteries (MCA) after organ culture.
This upregulation is dependent on mitogen-activated protein kinases and possibly protein kinase C
(PKC). The aim of this study was to examine the effect of PKC inhibitors with different profiles on
the upregulation of contractile ETB receptors in rat MCA. Artery segments were incubated for 24
hours at 37°C. To investigate involvement of PKC, inhibitors were added to the medium before
incubation. The contractile endothelin-mediated responses were measured and real-time PCR was
used to detect endothelin receptor mRNA levels. Furthermore, immunohistochemistry was used
to demonstrate the ETB receptor protein distribution in the MCA and Western blot to measure
which of the PKC subtypes that were affected by the inhibitors.
Results:  The PKC inhibitors bisindolylmaleimide I, Ro-32-0432 and PKC inhibitor 20–28
attenuated the ETB  receptor mediated contractions. Furthermore, Ro-32-0432 and
bisindolylmaleimide I decreased ETB receptor mRNA levels while PKC inhibitor 20–28 reduced the
amount of receptor protein on smooth muscle cells. PKC inhibitor 20–28 also decreased the
protein levels of the five PKC subtypes studied (α, βI, γ, δ and ε).
Conclusion:  The results show that PKC inhibitors are able to decrease the ETB receptor
contraction and expression in MCA smooth muscle cells following organ culture. The PKC
inhibitor 20–28 affects the protein levels, while Ro-32-0432 and bisindolylmaleimide I affect the
mRNA levels, suggesting differences in activity profile. Since ETB receptor upregulation is seen in
cerebral ischemia, the results of the present study provide a way to interfere with the vascular
involvement in cerebral ischemia.
Background
The endothelins constitute a group of vasoactive peptides
mainly produced by vascular endothelial cells [1]. There
are two known endothelin receptors in mammals and
both are found in the vascular wall. Normally, the
endothelin A (ETA) receptors are situated on the smooth
muscle cells in arteries where they give rise to contrac-
tions, while the ETB  receptors are primarily seen on
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endothelial cells. An activation of the endothelial ETB
receptors will lead to dilatation [2]. Interestingly enough,
after organ culture of arteries [3], experimental ischemic
stroke [4] and experimental subarachnoid hemorrhage [5]
there is an upregulation of contractile ETB  receptors
located on the smooth muscle cells of cerebral arteries. We
have revealed that this upregulation, when occurring in
organ culture, is dependent on mitogen-activated protein
kinases (MAPKs) [6] and possibly protein kinase C (PKC)
[7,8].
PKC was first discovered in 1977 [9], and comprises a
family of serine/threonine kinases, which is divided into
the conventional, the novel and the atypical PKCs [10-
12]. The PKCs participate in a wide variety of intracellular
signalling cascades and are activated by different stimuli,
such as growth factors, hormones and neurotransmitters
[12].
The PKC inhibitors Ro-31-8220 and Ro-31-7549, used in
previous studies of ETB receptor upregulation [7,8], have
been shown to affect other intracellular signalling mole-
cules, for example c-Jun N-terminal kinase and MAPK
phosphatase-1 [13,14]. Consequently there is a risk that
the effect of the PKC inhibitors may be due to inhibition
of other pathways rather than the PKC signalling pathway.
The aim of this study was therefore to establish the
involvement of PKC in the upregulation of contractile ETB
receptors in rat middle cerebral arteries (MCAs) during 24
hours of organ culture. This duration has proven to be an
optimal time for obtaining an upregulation of contractile
ETB receptors [7]. Subsequently, we wanted to examine
where in the process of upregulation the PKCs were
involved. This was done using a variety of PKC inhibitors
which affect PKC in different manners. The endothelin
receptors were examined both functionally with myo-
graphs, and on a molecular level with real-time PCR.
Immunohistochemistry was used to visualize the distribu-
tion of ETB receptors on the arterial smooth muscle cells.
Finally, Western blot was used to examine the levels of dif-
ferent PKC subtypes in the arteries after incubation with
the PKC inhibitors.
The general PKC inhibitors tested, all of which are cell per-
meable, had different effects on the vascular ETB receptor
upregulation. Bisindolylmaleimide I (Bis I), Ro-32-0432
and PKC inhibitor 20–28 (PKCi 20–28) all significantly
affected the sarafotoxin 6c (S6c, selective ETB receptor ago-
nist) induced contractility. In addition, Ro-32-0432
decreased the ETB receptor mRNA levels, as did Bis I to
some extent. PKCi 20–28 had no such effect. However,
PKCi 20–28 did reduce the amount of ETB receptor pro-
tein in the arteries and also decreased the protein amount
of the five PKC subtypes tested (α, βI, γ, δ and ε).
Results
Contractile experiments
K+-induced contractions did not differ between the con-
trol group and the arteries incubated with each of the PKC
inhibitors (data not shown). Previous studies have shown
that S6c does not induce contraction of fresh MCA seg-
ments [6,7]. After organ culture S6c produces contraction
of cerebral arteries due to the enhanced expression of
smooth muscle ETB receptor. In the present study, the S6c
induced contraction was significantly decreased in the
arteries cultured with the PKC inhibitors Bis I, Ro-32-0432
and PKCi 20–28 as compared to control (Table 1, fig. 1).
Ro-32-0432 also affected the pEC50 value of the S6c dose
response curve considerably (Table 1, P < 0.001). The PKC
inhibitor chelerythrine chloride had no effect on the S6c
induced contraction and was therefore not included in the
subsequent experiments (Table 1). After addition of S6c,
the ETB receptors are desensitized and a subsequent appli-
cation of endothelin-1 (ET-1, ETA/ETB agonist) only affects
the remaining contractile ETA receptors [15].
In the present study we found that the PKC inhibitors did
not have any effect on neither the maximum ET-1 induced
contraction nor on the pEC50 value of the ET-1 concentra-
tion-response curve (Table 1, P > 0.05).
mRNA analysis
mRNA was analyzed with real-time PCR and standard
curves were produced for each primer pair showing that
all samples were within the linear amplification range.
The slopes of the curves were close to 3.3, thus the ampli-
fication was close to optimal (data not shown).
The results of the real-time PCR showed that Ro-32-0432
decreased the ETA receptor and ETB receptor mRNA levels
significantly as compared to control (ETA receptor : 0.004
± 0.0002 compared to 0.018 ± 0.001; ETB receptor: 0.039
± 0.002 compared to 0.12 ± 0.005, Figs. 2A–B). Bis I
behaved similarly in decreasing the ETB receptor mRNA
levels, however not significantly (0.04 ± 0.003 compared
to 0.12 ± 0.005, P = 0.0615, Fig 2B). PKCi 20–28 had no
effect on the endothelin receptor mRNA levels (Figs. 2A–
B).
Receptor protein expression
Immunohistochemistry showed a clear decrease of ETB
receptors in the arteries treated with PKCi 20–28 in com-
parison to control (57% ± 4% of the control value, P <
0.05, Fig. 3). There was a small decrease in ETB receptor
density in the arteries treated with Ro-32-0432 (89% ± 9%
of control value) and Bis I (75% ± 13% of control value),
however it was not significant.BMC Pharmacology 2006, 6:13 http://www.biomedcentral.com/1471-2210/6/13
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PKC subtype expression
Western blot experiments were carried out using antibod-
ies directed specifically against phosphorylated, and
thereby activated, PKC isoforms (α, βI, γ, δ and ε). These
tests showed that PKCi 20–28 was able to decrease the
protein amount of all five PKC subtypes tested, although
the decrease was most prominent for PKCδ (38% ± 20%
of control, Fig. 4A) and PKCγ (51% ± 36% of control, Fig.
4B). Conversely Ro-32-0432 and Bis I did not decrease the
protein levels of the PKC subtypes.
Discussion
This study shows that each of the three general PKC inhib-
itors attenuates the organ culture induced upregulation of
the ETB receptor mediated contraction seen in rat MCA. A
fourth PKC inhibitor, chelerythrine chloride, had no
effect on the contractile responses of the arteries, and con-
sequently was not included in the additional experiments.
A possible explanation to this lack of effect could be that
chelerythrine chloride has been shown to alter vasocon-
strictive responses through interaction with various phos-
Table 1: Contractile responses to S6c and ET-1 in MCA incubated with four different PKC inhibitors
S6c ET-1
n Emax (%) pEC50 Emax (%) pEC50
Control 10 131 ± 7 9.13 ± 0.10 152 ± 6 8.74 ± 0.12
Bisindolylmaleimide I 14 73 ± 8** 8.97 ± 0.08 143 ± 6 8.70 ± 0.08
Chelerythrine chloride 9 102 ± 7 8.95 ± 0.20 139 ± 6 8.77 ± 0.18
PKC inhibitor 20–28 14 67 ± 10** 8.80 ± 0.16 145 ± 7 8.64 ± 0.17
Ro-32-0432 9 6 ± 3*** 8.92 ± 0.07*** 194 ± 12 8.36 ± 0.09
*P < 0.05, **P < 0.01, ***P < 0.001 compared to control. n represents the number of artery segments.
Contractile response towards S6c Figure 1
Contractile response towards S6c. Contractile responses towards the ETB receptor agonist S6c in MCAs incubated for 24 
hours (control) and MCAs incubated for 24 hours with PKC inhibitors (Bis I, Ro-32-0432, PKCi 20–28). Each point represents 
mean value ± S.E.M. For statistical analysis, see Table 1.
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phodiesterases and thus lacks specificity [16].
Furthermore, chelerythrine chloride activates c-Jun N-ter-
minal kinase pathways [17]. Our group has recently dis-
covered that c-Jun N-terminal kinase plays an important
role in the upregulation of ETB receptors in porcine coro-
nary arteries (Nilsson et al., unpublished data), which
could explain why chelerythrine chloride fails to inhibit
the ETB receptor upregulation in the present study.
Bis I and Ro-32-0432 are both competitive inhibitors for
the ATP-binding site of PKC [18,19], but in a slightly dif-
ferent manner, which results in differences in PKC sub-
type affinity. Bis I inhibits the conventional PKCs
(subtypes α, βI, βII and γ) with similar potency (IC50 = 10
nM) [18], and the subtypes δ and ε to a lesser extent [20].
Ro-32-0432 mainly affects the α subtype (IC50 = 9 nM),
but also βI, βII and γ [19].
The third inhibitor tested, the PKC inhibitor 20–28, is a
pseudosubstrate peptide, which mimics a particular
domain of the PKC that keeps the enzyme in an inactive
state [21]. The peptide is based on the pseudosubstrate
motif of PKCα and β and is myristoylated to allow cell
membrane permeability. All these three PKC inhibitors
Endothelin receptor mRNA levels Figure 2
Endothelin receptor mRNA levels. ETA receptor and ETB receptor mRNA levels relative to EF-1. MCAs incubated for 24 
hours (control) are compared to MCAs incubated for 24 hours with PKC inhibitors (Bis I, Ro-32-0432, PKCi 20–28). Data are 
presented as mean values ± S.E.M. *P < 0.05, **P < 0.01.
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significantly reduced the organ culture induced upregula-
tion of the ETB receptor mediated contraction.
The real-time PCR showed that Ro-32-0432 and, to a cer-
tain extent, Bis I blocked the elevated levels of ETB receptor
mRNA relative to that seen in the control arteries. How-
ever, PKCi 20–28 failed to exhibit this effect on the mRNA
level. Instead, PKCi 20–28 diminished ETB receptor pro-
tein expression. One reason for this discrepancy could be
that Ro-32-0432 and Bis I exert their inhibitory effects ear-
lier in the production of ETB receptors in the arteries, pos-
sibly upstream from gene level, causing a decrease of the
ETB  receptor mRNA. PKCi 20–28 on the other hand,
affects the ETB receptor protein production and not the
mRNA levels and hence at a translational level. In concert
the PKCi 20–28 decreased the amount of ETB receptor pro-
tein as shown by immunohistochemistry, and marginally
in the case of Bis I and Ro-32-0432. Nevertheless, a small
decrease could be enough to diminish the functional
response. Thus, the results could be interpreted to show a
multiple role for PKC in the upregulation of ETB receptors.
Another explanation for the difference between the
mRNA levels and the protein levels in the case of PKCi
20–28 is that the inhibiting effect may not be as pro-
longed as for the two other inhibitors and subsequently,
at the time point measured, the ETB receptor mRNA might
be restored to its normal level.
The ETA receptor mRNA in rat cerebral arteries is not
altered by 24 hours of organ culture [7]. Still, Ro-32-0432
did decrease the ETA receptor mRNA levels after incuba-
tion. This was not accompanied by a diminished ETA
receptor mediated contraction. This discrepancy could be
due to the fact that the mRNA levels do not necessarily
reflect the presence of functional receptors, and at a later
time point, the ETA receptor density will decrease.
Previous studies with the PKC inhibitors Ro-31-8220 and
Ro-31-7549 indicate that the conventional PKC subtypes
(α, β, γ) are involved in the ETB receptor alteration after
organ culture [7,8]. The present study confirms this, but
also shifts the focus slightly towards the PKCδ subtype.
This is interesting, since several studies have shown PKCδ
to be deleterious in experimental ischemia [22-24]. For
example, treatment with PKCδ inhibitors decreases infarct
size [25], and PKCδ knock-out mice show a decreased inf-
arct size compared to wild type mice [26]. Further studies
need to be done to define the role of PKCδ in our experi-
mental setting.
We have previously shown that in both experimental focal
ischemia and subarachnoid hemorrhage there is an ETB
receptor upregulation in the MCA [4,5]. This upregulation
may lead to enhanced contraction of the arteries, which
causes an attenuation of blood and oxygen supply to the
infarcted area, and subsequently an aggravation of the
ischemic damage. Thus, according to our findings here, a
beneficial effect of PKC inhibition in ischemia could in
part be due to a reduction of the ETB receptor upregulation
in the cerebral arteries.
Distribution of ETB receptor protein Figure 3
Distribution of ETB receptor protein. Expression of ETB receptor protein in a) MCA incubated for 24 hours (control) and 
b) MCA incubated for 24 hours with addition of PKCi 20–28.
      
A. Control        B. PKCi 20-28 BMC Pharmacology 2006, 6:13 http://www.biomedcentral.com/1471-2210/6/13
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Conclusion
This study demonstrates that PKC inhibitors are able to
decrease the ETB receptor contraction and expression in
smooth muscle cells of MCA following 24 hours of organ
culture. A similar upregulation of contractile ETB receptors
has been seen in an experimental model of focal ischemia.
The results of the present study can therefore be of signif-
icance in finding new therapeutic targets in cerebral
ischemia.
Methods
Artery preparation and organ culture procedure
The experimental procedures were approved by the Ethics
Committee for Laboratory Animal Experiments at Lund
University (Application number M 217-03).
Male Wistar rats (350–400 g, M & B, Denmark) were anes-
thetized with CO2 and decapitated. The right and left MCA
were removed and dissected free from surrounding tissue.
The arteries were cultured for 24 hours in Dulbeccos mod-
ified Eagle's medium (DMEM), supplemented with peni-
cillin (100 U/ml), streptomycin (100 μg/ml) and
amphotericin B (25 μg/ml), at 37°C in humidified 5%
CO2 in air. This induces a maximal ETB receptor upregula-
tion [7]. The inhibitors were added to the medium before
the incubation (Bis I, 10 μM; Ro-32-0432, 10 μM; cheler-
ythrine chloride, 1 μM and PKCi 20–28, 100 μM). The
choice of dose was based on Ki values and on previous
studies using the inhibitors. Pilot experiments were done
to determine the optimal doses in this setting.
Myograph experiments
After incubation, the arteries were cut into cylindrical seg-
ments. The segments were mounted on two 40 μm diam-
eter stainless steel wires in a Mulvany-Halpern myograph
(Danish Myo Technology A/S, Denmark) [27,28]. One of
the wires was connected to a force transducer attached to
an analogue-digital converter unit (ADInstruments, Hast-
ings, UK). The other wire was attached to a movable dis-
placement device allowing adjustments of vascular
tension by varying the distance between the wires. The
experiments were recorded on a computer by use of the
software program Chart™ (ADInstruments, UK). The seg-
ments were immersed in a temperature-controlled (37°C)
bicarbonate buffer (for composition, see below). The
buffer was continuously gassed with 5% CO2 in O2, result-
ing in a pH of 7.4. The arteries were given an initial ten-
sion of 1.2 mN, and were allowed to adjust to this level of
tension for 1 hour. The contractile capacity was deter-
mined by exposure to a potassium-rich (63.5 mM) buffer
(for composition, see below). Concentration-response
curves for the agonists S6c (ETB receptor agonist) and ET-
1 (ETA and ETB receptor agonist) were obtained by cumu-
lative application (10-12-10-6.5 M). Following sarafotoxin
6c administration, the endothelin ETB receptors are desen-
sitized, leaving only endothelin ETA receptors to interact
with endothelin-1 [15].
Calculations
The Emax values represent the maximum vascular contrac-
tion as response to S6c or ET-1 and were calculated as per-
centage of the contractile response towards 63.5 mM K+.
The pEC50 values represent the negative logarithm of the
concentration which elicits half-maximum response. Data
are expressed as mean values ± S.E.M. Statistical analyses
were performed with Kruskal-Wallis non-parametric test
with Dunn's post-hoc test. P < 0.05 is considered signifi-
cant. There were 3–5 rats in each group, with 1–4 seg-
ments from each. n  refers to the number of arterial
segments.
Real-time PCR
Total cellular RNA was extracted from each MCA using the
FastRNA Pro Green Kit following the suppliers' instruc-
tions. The resulting pellet was finally washed with 75%
ethanol, air-dried and redissolved in diethylpyrocar-
bonate-treated water. Reverse transcription of total RNA
to cDNA was carried out using the GeneAmp RNA PCR kit
in a Perkin-Elmer DNA Thermal cycler, using random hex-
amers as primers. The reaction mixture was incubated at
25°C for 10 minutes, 42°C for 30 minutes, heated to
99°C for 5 minutes and chilled to 5°C for 5 minutes.
PKC subtype expression Figure 4
PKC subtype expression. Expression of phosphorylated 
PKCδ protein (A) and PKCγ protein (B) in MCAs incubated 
for 24 hours (control) and MCAs incubated for 24 hours 
with PKC inhibitors.
Control  PKCi     Bis      Ro 
Control  PKCi   Bis      Ro
pPKC δ
pPKC γBMC Pharmacology 2006, 6:13 http://www.biomedcentral.com/1471-2210/6/13
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Real-time PCR was performed in a GeneAmp 5700
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) using the GeneAmp SYBR® Green kit with
the cDNA synthesized above as template in a 50 μl reac-
tion volume. A no template control was included in all
experiments. This technique consists of an optic imaging
system that is able to monitor the amount of DNA in each
PCR cycle via the detection of a fluorescent dye binding to
double-stranded DNA. The DNA levels of the genes of
interest are compared to an endogenous standard. In this
study, specific primers for the rat ETA and ETB receptors
were designed as follows: ETA receptor, forward: 5'-ATT-
GCCCTCAGCGAACAC-3'; reverse: 5'-CAACCAAGCA-
GAAGACGGTC-3', ETB  receptor forward:
5'GATACGACAACTTCCGCTCCA-3'; reverse: 5'-GTCCAC-
GATGAGGACAATGAG-3'. Elongation factor-1 (EF-1)
mRNA was used as an endogenous standard. The EF-1
primers were designed as follows: forward; 5'-
GCAAGCCCATGTGTGTTGAA-3'; reverse: 5'-TGAT-
GACACCCACAGCAACTG-3'. The real-time PCR was car-
ried out as follows: 50°C for 2 minutes, 95°C for 10
minutes, 40 cycles of 95°C for 15 seconds and 60°C for 1
minute. Each sample was examined in duplicates.
Calculations
The amount of ETA receptor and ETB receptor mRNA was
calculated as relative to the amount of EF-1 mRNA in the
same sample by the formula: X0/R0 = 2CtR-CtX, where X0 =
original amount of endothelin receptor mRNA, R0 = orig-
inal amount of elongation factor-1 mRNA, CtR = CT-value
for elongation factor-1 and CtX = CT-value for the
endothelin receptor. Each sample was examined in dupli-
cates and the mean values were used.
Data are expressed as mean values ± S.E.M. Statistical
analyses were performed with Kruskal-Wallis non-para-
metric test with Dunn's post-hoc test. P < 0.05 is consid-
ered significant. n = 6–7, where n is the number of MCAs
used.
Immunohistochemistry
After incubation for 24 hours, the MCAs were placed onto
Tissue TEK, frozen and subsequently sectioned into 10 μm
slices. The primary antibodies used were rabbit-antihu-
man endothelin ETB receptor antibody, diluted 1:400,
goat-antimouse endothelin ETA receptor antibody, diluted
1:100 and mouse-antirat CD31 antibody, diluted 1:200.
The secondary antibodies used were donkey-antirabbit
Cy™3 conjugated, diluted 1:100, donkey-antigoat Cy™2
conjugated, diluted 1:100, and donkey-antimouse Cy™5
conjugated, diluted 1:100. All dilutions were done in
phosphate buffered saline with 10% fetal calf serum. The
antibodies were then detected at the appropriate wave-
length in a confocal microscope (Zeiss, USA). As control,
only addition of secondary antibodies was used.
Calculations
The images were analysed using the ImageJ software [29].
The fluorescence in 4–6 different areas in each artery was
measured and a mean value was calculated. These values
are presented as percentage fluorescence in the treated
groups compared to the control group, where the control
group was set to 100%. Data are expressed as mean values
± S.E.M with three arteries from three different rats in each
group. Statistical analyses were performed with Kruskal-
Wallis non-parametric test with Dunn's post-hoc test. P <
0.05 is considered significant.
Western Blot
After incubation, the MCAs were collected and placed on
ice, homogenized in lysis-buffer with protease- and phos-
phatase inhibitors (for composition, see below). After 20
minutes incubation in lysis buffer on ice, homogenates
were centrifuged at 4500 g for 10 min at 4°C and super-
natant collected. Total protein concentration was deter-
mined using a BioRad DC kit (Hercules, CA, USA) and the
absorbance was measured at 750 nm on a Genesys 10
spectrophotometer (Thermo, Waltham, MA, USA).
Lysates were dissolved in Tris-glycine SDS sample buffer
(Invitrogen A/S, Taastrup, Denmark) and boiled for 5
minutes. Equal amounts of protein (10 μg/lane) were
loaded on a 8% Tris-glycine gel (Invitrogen A/S, Taastrup,
Denmark) and separated by SDS-polyacrylamide gel elec-
trophoresis. Molecular weight markers (New England
BioLabs, Ipswich, MA, USA) were loaded on each gel for
protein band identification. After separation, proteins
were transferred to a nitrocellulose membrane (BioRad,
Hercules, CA, USA). Subsequently the membrane was
blocked with 6.5% non-fat milk in Tween-TBS overnight
at 4°C. Membranes were then incubated with the follow-
ing primary antibodies: rabbit polyclonal anti-PKCα
phosphospecific (1:1000 dilution), rabbit polyclonal
anti-PKCδ phosphospecific (1:1000 dilution), rabbit pol-
yclonal anti-PKCε phosphospecific (1:1000 dilution),
rabbit polyclonal anti-PKCβI phosphospecific (1:1000
dilution), rabbit polyclonal anti-PKCγ phosphospecific
(1:1000 dilution) or mouse polyclonal β-actin overnight
at 4°C, followed by 3 × 5 minutes wash with Tween-TBS.
Thereafter, the membranes were incubated with the
appropriate secondary antibody: goat anti-rabbit IgG-
horseradish peroxidase or goat anti-mouse IgG-horserad-
ish peroxidase (1:5000) for 1 hour at room temperature,
followed by 5 × 5 minutes wash with Tween-TBS. Levels of
β-actin were used to confirm equal loading of the lanes.
The membranes were developed using the Supersignal
Dura kit (Pierce, Rockford, IL, USA) and visualized using
a Fujifilm LAS-1000 Luminiscent Image Analyzer (Stam-
ford, CT, USA).BMC Pharmacology 2006, 6:13 http://www.biomedcentral.com/1471-2210/6/13
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Calculations
Protein lysates from the four different groups were com-
pared. MCAs from three animals were pooled for each
sample and each group consisted of three samples. Quan-
tification of band density was performed with the electro-
phoresis computer analysis program Fujifilm Science Lab
Image Gauge 4.0. The immunoblot optical density values
were determined with repeated measurements and are
presented as percentage activity in the groups treated with
PKC inhibitors compared to the control group, where the
control group was set to 100%. All values are relative to
the respective β-actin band density. Data are expressed as
mean values ± S.E.M.
Drugs and chemicals
The bicarbonate buffer had the following composition
(mM): NaCl 119; NaHCO3  15; KCl 4.6; MgCl2  1.2;
NaH2PO4 1.2; CaCl2 1.5 and glucose 5.6, while the potas-
sium-rich bicarbonate buffer composition was as follows
(mM): NaCl 59.5; NaHCO3 15; KCl 63.5; MgCl2 1.2;
NaH2PO4 1.2; CaCl2 1.5 and glucose 5.6.
The DMEM supplemented with penicillin (100 U/ml),
streptomycin (100 μg/ml) and amphotericin B (25 μg/
ml) was purchased from Gibco (Stockholm, Sweden).
Bis I, Ro-32-0432, chelerythrine chloride and PKCi 20–28
were purchased from Calbiochem (San Diego, CA, USA)
and dissolved in dimethyl-sulfoxide. ET-1 and S6c (Alexis
Biochemicals, Lausen, Switzerland) were dissolved in
0.9% saline with 0.1% bovine serum albumin.
FastRNA Pro Green Kit was purchased from BIO 101
(Carlsbad, CA, USA).
GeneAmp RNA PCR kit and GeneAmp SYBR® Green kit
were purchased from Applied Biosystems (Foster City, CA,
USA).
For the immunohistochemistry, Tissue TEK was pur-
chased from Gibco (Stockholm, Sweden). Rabbit-antihu-
man ETB  receptor antibody was purchased from IBL
(Gunma, Japan), goat-antimouse ETA receptor antibody
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA)
and mouse-antirat CD31 antibody from Serotec (Oxford,
UK). The secondary antibodies, donkey-antimouse Cy™5
conjugated, donkey-antirabbit Cy™3 conjugated and don-
key-antigoat Cy™2 conjugated, were purchased from Jack-
sonImmunoResearch (Gothenburg, Sweden).
The lysis-buffer for Western blot had the following com-
position: 10 mM Tris pH 7.4, 50 mM β-Glycerophos-
phate, 100 μM Na3VO4, 0.5% Deoxycholate, 1 mM EGTA,
1 mM EDTA, 1 mM NaF, 20 mM Na4P2O7, 1% Triton X-
100, 1 mM DTT, 20 μM Pepstatin, 20 μM Leupeptin, 0.1
U/ml Aprotinin, 1 nM Calyculin and 1 mM PMSF.
The primary antibodies for the Western blot were rabbit
polyclonal antibodies with following specificity: anti-
PKCα phosphospecific (phosphorylated at threonine
638), anti-PKCδ phosphospecific (phosphorylated at ser-
ine 664), anti-PKCε phosphospecific (phosphorylated at
serine 739), anti-PKCβI phosphospecific (phosphorylated
at threonine 642) and anti-PKCγ phosphospecific (phos-
phorylated at threonine 655) were purchased from Bio-
source (Camarillo, CA, USA). The mouse polyclonal β-
actin antibody was purchased from Sigma (Saint Louis,
USA). The secondary antibodies; goat anti-rabbit IgG-
horseradish peroxidase and goat anti-mouse IgG-horse-
radish peroxidase were purchased from Pierce (Rockford,
IL, USA).
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